UPDATE: Jefferies Raises PT on Integra Life-Sciences Holdings from $40 to $43

Jefferies maintained a Buy rating on Integra Life-Sciences Holdings IART and raised its price target from $40 to $43. Jefferies wrote, “Integra reported better-than-expected 2Q results. While broader end market challenges remain, particularly internationally, with better execution the of the growth strategy the story appears back on track. We continue to rate the shares Buy and increase our one-year target to $43 from $40.” Integra Life-Sciences Holdings closed at $38.13 on Thursday.